Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNFRSF1A | P19438 | 4/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.44 |
| ▸ | ERN1 | O75460 | 2/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.40 |
| ▸ | APP | P05067 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6091040 | 0.91 | TNFRSF1A (0.53) | TNFRSF1AHDAC6ERN1NPC1RAB9A | |
| SCHEMBL732990 | 0.82 | APP (0.58) | TNFRSF1AHDAC6ERN1MAPTHDAC2 | |
| SCHEMBL6092548 | 0.81 | KDM4E (0.50) | TNFRSF1AHDAC6HIF1ANPC1RAB9A | |
| SCHEMBL6092281 | 0.76 | ALPL (0.50) | NPC1RAB9AMAPTMEN1KMT2A | |
| SCHEMBL6091620 | 0.75 | TNFRSF1A (0.52) | TNFRSF1AHDAC6NPC1RAB9AMAPT | |
| SCHEMBL6091489 | 0.75 | HDAC1 (0.43) | ERN1HIF1ANPC1MAPTHDAC2 | |
| SCHEMBL6093398 | 0.73 | TNFRSF1A (0.50) | TNFRSF1AHDAC6ERN1NPC1RAB9A | |
| SCHEMBL6091795 | 0.73 | CYP19A1 (0.59) | MEN1KMT2A | |
| SCHEMBL10436312 | 0.73 | TNFRSF1A (0.61) | TNFRSF1AERN1NPC1RAB9AS1PR1 | |
| SCHEMBL6094331 | 0.72 | KMT2A (0.49) | HIF1ANPC1MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060063828-A1 | 1,2-Bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof | ATHEROGENICS, INC. | 2006-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063828-A1 | 1,2-Bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof | ABCB11, CEL, CYP46A1 | TNFRSF1A 4880/4885HDAC6 459/4885ERN1 2367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.